Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (98)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (5)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (297)
  2. Department of Medicine (297)
  3. Hematologic Malignancies, Division of (297)
  4. Myeloma (297)
  5. Survivorship Research (216)
  6. Hematologic Malignancies Research (212)

More Groups

People
  1. Neha Korde (191)
  2. Alexander Lesokhin (170)
  3. Hani Hassoun (163)
  4. Sergio Giralt (161)
  5. Malin Hultcrantz (158)
  6. Heather Landau (147)

More People

Years
  1. 2025 (13)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (96)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. Blood Cancer Journal (12)
  5. JAMA Oncology (12)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (107)
  2. Elsevier Inc. (71)
  3. Nature Publishing Group (26)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (297)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Interim results of a phase 2 trial of isatuximab-lenalidomide for patients with High-Risk Smoldering Multiple Myeloma
    Meeting Abstract

    Thomas, S.; Manasanch, E.; Korde, N.; Lee, H.; Jagannath, S.; Becnel, M.; Kaufman, G.; Patel, K.; Iyer, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; Garcés, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?
    Review

    Rajeeve, S.; Hoskote, A.; Mailankody, S.
    Seminars in Hematology (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C. R. C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Shah, G. L.; Scordo, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Meeting Abstract

    Tan, C. R. C.; Rueda, C.; Shekarkhand, T.; Derkach, A.; Korde, N.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save